CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...
CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...
CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...

WELCOME
ON THE CONDOR PROGRAM WEBSITE

CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas (STS) patients.

STS are rare tumours of mesenchymal origin, comprising ~1% of all adult cancers and 15% in children, +4,500 adults and children each year in France, and 500,000 worldwide. Up to 40% of STS patients will develop metastatic disease.

THE PROJECT

1 coordinator + 7 strategic partners = 1 objective:

Establishing immunotherapy as a standard for sarcoma

This project has benefited from a government grant managed by the French National Research Agency (ANR) 
under the 3rd Investments for the Future program (PIA) , integrated into France 2030
with the reference
ANR-21-RHUS-0010.

CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...
CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...

CONSORTIUM

CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas patients with 1 coordinator + 7 strategic partners...

EVENTS & PRESENTATION

SUBSCRIBE
TO OUR
NEWSLETTER